发布求助
文献互助 智能选刊 最新文献

Oncology (Williston Park, N.Y.)最新文献

筛选
英文 中文
The Expanding Role of Immunotherapy. 免疫疗法的作用日益扩大。
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0427
{"title":"The Expanding Role of Immunotherapy.","authors":"","doi":"10.46883/ONC.2020.3410.0427","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0427","url":null,"abstract":"<p><p>ONCOLOGY® recently spoke with Mario Sznol, MD, professor of medicine (medical oncology) at Yale School of Medicine and Yale Cancer Center, about the rapidly expanding use of immunotherapies, the future of immuno-oncology, and the management of immune-related toxicities.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"427-429"},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38492805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC. FDA批准普拉塞替尼用于治疗成人转移性RET融合阳性NSCLC。
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0406
Kevin M Wright
{"title":"FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.","authors":"Kevin M Wright","doi":"10.46883/ONC.2020.3410.0406","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0406","url":null,"abstract":"<p><p>The US FDA granted accelerated approval to pralsetinib for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"406-406;431"},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38492802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Hematologic Malignancies Pipeline. 血液恶性肿瘤管道。
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0430
{"title":"Hematologic Malignancies Pipeline.","authors":"","doi":"10.46883/ONC.2020.3410.0430","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0430","url":null,"abstract":"","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"430-431"},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38492806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy. 在接受新辅助内分泌治疗的乳腺癌患者中优化腋窝手术策略。
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0397
Anna Weiss, Elizabeth A Mittendorf, Tari A King
{"title":"Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy.","authors":"Anna Weiss,&nbsp;Elizabeth A Mittendorf,&nbsp;Tari A King","doi":"10.46883/ONC.2020.3410.0397","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0397","url":null,"abstract":"<p><p>Current guidelines for axillary surgery following systemic therapy do not differentiate between neoadjuvant endocrine therapy (NET) and neoadjuvant chemotherapy (NAC). Without specific guidelines, many assume that axillary surgery after NET should mirror that after NAC; however, NET has traditionally been used for patients with biologically favorable disease, so alternative axillary surgery strategies may be appropriate. Unfortunately, clinical trials that have examined NET have not rigorously studied axillary management or outcomes. The limited observational data available reveal that axillary lymph node dissection (ALND) is less frequently performed for positive nodes following NET than NAC; ALND rates after NET are more like those of upfront surgery patients. Although outcomes of omitting ALND after NET in patients who remain node positive are unknown, hypothesis-generating work from the National Cancer Database suggests that most patients selected for NET have limited nodal burden, and the prognostic significance of residual nodal disease after NET may not carry the same implications as residual disease after NAC. As such, there is opportunity to define axillary surgery strategies after NET that differ from those used after NAC.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"397-404"},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38492801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Barriers to Pancreatic Clinical Trials Enrollment. 胰腺临床试验入组的障碍。
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0407.1
Shubham Pant, Michael S Lee
{"title":"Barriers to Pancreatic Clinical Trials Enrollment.","authors":"Shubham Pant,&nbsp;Michael S Lee","doi":"10.46883/ONC.2020.3410.0407.1","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0407.1","url":null,"abstract":"<p><p>Pancreatic cancer is the third leading cause of cancer mortality in the United States, causing an estimated 47,050 deaths in the year 2020, and had the lowest 5-year relative survival of any cancer type diagnosed in 2009-2015, at only 9%. In light of this limited prognosis, consensus guidelines from ASCO and NCCN recommend that patients be informed about and/or managed in clinical trials. However, only 4.16% of patients with pancreatic cancer ultimately enrolled in clinical trials in 2014, while enrollment to existing trials is noted to be unacceptably slow.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38523086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Disorders of Sex Development and Malignant Germ Cell Tumors. 性发育障碍与恶性生殖细胞肿瘤。
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0421
Miguel Araujo-Melendez, Haydee Verduzco-Aguirre, Juan J Morales, Braulio Martinez-Benitez, Ricardo Castillejos-Molina, Alejandro Fuentes, Mahmoud Salama, Maria T Bourlon
{"title":"Disorders of Sex Development and Malignant Germ Cell Tumors.","authors":"Miguel Araujo-Melendez,&nbsp;Haydee Verduzco-Aguirre,&nbsp;Juan J Morales,&nbsp;Braulio Martinez-Benitez,&nbsp;Ricardo Castillejos-Molina,&nbsp;Alejandro Fuentes,&nbsp;Mahmoud Salama,&nbsp;Maria T Bourlon","doi":"10.46883/ONC.2020.3410.0421","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0421","url":null,"abstract":"<p><p>A woman, aged 44 years, presented at the general oncology outpatient clinic with bloating, abdominal pain, and significant unintended weight loss. Her past medical history included a bilateral inguinal hernia surgical repair at age 6, and primary amenorrhea since age 15. The patient never underwent additional studies to identify the cause of the primary amenorrhea.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"421-426"},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38492804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Considerations for the Management of Oncology Patients During the COVID-19 Pandemic. COVID-19大流行期间肿瘤患者管理的几点考虑
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0432
Julie Huang, Abhinav Rohatgi, Jeffrey Schneider, Marc Braunstein
{"title":"Considerations for the Management of Oncology Patients During the COVID-19 Pandemic.","authors":"Julie Huang,&nbsp;Abhinav Rohatgi,&nbsp;Jeffrey Schneider,&nbsp;Marc Braunstein","doi":"10.46883/ONC.2020.3410.0432","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0432","url":null,"abstract":"<p><p>Worldwide incidence and mortality due to the coronavirus disease 2019 (COVID-19) pandemic is greatest in the United States, with the initial epicenter in New York. In Nassau County, New York, where we practice, our institution has had more than 2500 cases and has discharged from the hospital more than 1000 patients. As many academic and private institutions have swiftly shifted their clinical and research priorities to address the pandemic, data are emerging regarding both the impact of malignancy on COVID-19 outcomes as well as the challenges faced in assuring that cancer care remains unimpeded. Of concern, recent studies of cancer patients primarily in China and Italy have suggested that advanced malignancy is associated with increased susceptibility to severe COVID-19 infection. At present, more than 500 clinical trials are underway investigating the pathogenesis and treatment of COVID-19, including expanded use of oncology drugs, such as small molecular inhibitors of cytokine pathways. Here, we begin by reviewing the latest understanding of COVID-19 pathophysiology and then focus our attention on the impact of this virus on hematologic and oncologic practice. Finally, we highlight ongoing investigational treatment approaches that are so relevant to the care of oncology patients during this extraordinary pandemic.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"432-441"},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38492807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer. PARP抑制剂在卵巢癌一线维持治疗中的应用
Oncology (Williston Park, N.Y.) Pub Date : 2020-10-09 DOI: 10.46883/ONC.2020.3410.0442
{"title":"Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.","authors":"","doi":"10.46883/ONC.2020.3410.0442","DOIUrl":"https://doi.org/10.46883/ONC.2020.3410.0442","url":null,"abstract":"<p><p>Ovarian cancer is the leading cause of mortality among gynecologic cancers in the United States, expected to result in roughly 13,940 deaths in 2020. Between 2008 and 2017, mortality decreased by 2.3% per year. Incidence rates also decreased, with a 1.6% drop per year from 2007 to 2016. In 2020, an estimated 21,750 new cases of ovarian cancer will be diagnosed. The majority (90%) of ovarian cancers are epithelial ovarian cancer-often high-grade serous adenomas, which are associated with a poor prognosis and have the fewest known risk factors.</p>","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"442-444"},"PeriodicalIF":0.0,"publicationDate":"2020-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38492808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? 对照:格里森3+4前列腺癌是否应该使用主动监测?
Oncology (Williston Park, N.Y.) Pub Date : 2019-06-19
Ikenna Madueke, Michael R Abern
{"title":"Counterpoint: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?","authors":"Ikenna Madueke,&nbsp;Michael R Abern","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"235, 237-8, 242"},"PeriodicalIF":0.0,"publicationDate":"2019-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37346259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer? 观点:格里森3+4前列腺癌是否应该使用主动监测?
Oncology (Williston Park, N.Y.) Pub Date : 2019-06-19
Abhishek Bhat, Sanoj Punnen
{"title":"Point: Should Active Surveillance Be Used for Gleason 3+4 Prostate Cancer?","authors":"Abhishek Bhat,&nbsp;Sanoj Punnen","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":520728,"journal":{"name":"Oncology (Williston Park, N.Y.)","volume":" ","pages":"235-6"},"PeriodicalIF":0.0,"publicationDate":"2019-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37346258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信